Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Wix.com launches $1.75B modified Dutch auction to buy back shares at $80–$92 (SeekingAlpha) +++ WIX.COM Aktie +3,94%

SINO BIOPHARMACEUTICAL Aktie

 >SINO BIO Aktienkurs 
0.65 EUR    +3.0%    (TradegateBSX)
Ask: 0.65 EUR / 17856 Stück
Bid: 0.641 EUR / 7795 Stück
Tagesumsatz: 10039 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
SINO BIO Aktie über LYNX handeln
>SINO BIO Performance
1 Woche: -8,7%
1 Monat: -9,3%
3 Monate: -15,5%
6 Monate: -29,7%
1 Jahr: +61,5%
laufendes Jahr: -5,5%
>SINO BIOPHARMACEUTICAL Aktie
Name:  SINO BIOPHARMACEUTICAL
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG8167W1380 / A0CBDJ
Symbol/ Ticker:  SMZ1 (Frankfurt)
Kürzel:  FRA:SMZ1, ETR:SMZ1, SMZ1:GR
Index:  -
Webseite:  https://www.sinobiopharm...
Profil:  Sino Biopharmaceutical Ltd. is a diversified biopharmaceutical enterprise specializing in the research, development, manufacturing, and commercialization of a wide array of pharmaceuticals. The compan..
>Volltext..
Marktkapitalisierung:  11592.28 Mio. EUR
Unternehmenswert:  12133.9 Mio. EUR
Umsatz:  3621.47 Mio. EUR
EBITDA:  914.98 Mio. EUR
Nettogewinn:  441.12 Mio. EUR
Gewinn je Aktie:  0.02 EUR
Schulden:  1438.64 Mio. EUR
Liquide Mittel:  439.36 Mio. EUR
Operativer Cashflow:  1089.85 Mio. EUR
Bargeldquote:  0.8
Umsatzwachstum:  2.83%
Gewinnwachstum:  33.4%
Dividende je Aktie:  0.01 EUR
Dividendenrendite:  1.53%
Dividendenschätzung:  1.53%
Div. Historie:  29.08.25 - 0.005522€
16.06.25 - 0.0044176€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  SINO BIOPHARMACEUTICAL, SINO BIOPHARMA, SINO BIOPHARM, SINO BIO
Letzte Datenerhebung:  05.03.26
>SINO BIO Kennzahlen
Aktien/ Unternehmen:
Aktien: 17885.7 Mio. St.
Frei handelbar: 51.52%
Leerverk. Aktien: -
Rückkaufquote: 0.87%
Mitarbeiter: 24379
Umsatz/Mitarb.: 0.14 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 72.77%
Bewertung:
KGV: 24.61
KGV lG: 18.19
KUV: 3.14
KBV: 2.68
PEG-Ratio: 0.51
EV/EBITDA: 13.26
Rentabilität:
Bruttomarge: 81.77%
Gewinnmarge: 12.72%
Operative Marge: 20.82%
Managementeffizenz:
Gesamtkaprendite: 5.45%
Eigenkaprendite: 11.67%
>SINO BIO Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
05.03.26 - 05:30
Midday Takeaway: HSI Closes Midday at 25,462, Up 212 pts; HSTI Closes Midday Flat at 4,829; SINO BIOPHARM Up over 5%; KINETIC DEV Hit New Highs (AAStocks)
 
At midday close, HSI rose 212 pts or 0.8% to 25,462. HSTI stayed still at 4,829. HSCEI gained 20 pts or 0.2% to 8,504.Active Heavyweights:MEITUAN (03690.HK) closed at $74.1, down 1.7%XIAOMI (01810.HK) closed at $32.5, up 1.6%HKEX (00388.HK) closed at $410.4, up 1.4%BABA (09988.HK) closed at $128.4, down 1.2%TENCENT (00700.HK) cl......
04.03.26 - 13:00
Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
04.03.26 - 10:36
China outlicensing tops US$52 billion in first 2 months on rise in global deals (SCMP)
 
The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion. The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said. The latest deals, Sino Biopharmaceutical's agreement with......
04.03.26 - 00:57
Sino Biopharma signs up to $1.4 bln licensing deal with Sanofi (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
12.02.26 - 08:15
Research: BofAS: SINO BIOPHARM Shows Positive Progress on 2 Drugs; Rating Reiterated at Buy (AAStocks)
 
SINO BIOPHARM (01177.HK) has recently completed the enrollment of subjects for the Phase III clinical trials of two drugs, naming TQB2102 and LM302, BofA Securities issued a research report saying. Of which, LM302 is the world's first CLDN18.2 antibody-drug conjugate (ADC) to complete enrollment for a Phase III registrationa......
27.01.26 - 10:00
SINO BIOPHARM's TQA3605 'Core Protein Allosteric Modulator' for Chronic Hepatitis B Achieves Primary Endpoint in Phase II Clinical Trials (AAStocks)
 
SINO BIOPHARM (01177.HK) announced that the national Class I innovative drug, TQA3605 tablets "Core Protein Allosteric Modulator (CpAM)" independently developed by the group, has recently completed Phase II clinical trials for patients with chronic hepatitis B virus (HBV) infection and met the primary endpoint.In terms......
22.01.26 - 19:18
Sino Biopharma CEO on China′s Clinical Trial Growth (Bloomberg)
 
Sino Biopharmaceutical CEO Eric Tse discusses the "survival" necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on the sidelines of the 2026 World Economic Forum in Davos, Switzerland. (Source: Bloomberg)...
14.01.26 - 06:18
Sino Biopharm To Remain Active in M&A, Says Chair (Bloomberg)
 
Sino Biopharmaceutical Chairwoman Theresa Tse says her company is open to acquiring more biotech companies in China after announcing a new buyout. She also tells "Bloomberg: The China Show" that the company is looking for partnerships with bigger multinational firms. (Source: Bloomberg)...
13.01.26 - 06:15
Research: CMBI Expects LT Continuation of Innovative Drug Export Trend, Rates SINO BIOPHARM/ WUXI XDC/ Others at Buy (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
13.01.26 - 05:45
Research: CMBI Ratings, TPs on Pharma (Table) (AAStocks)
 
Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 SINO BIOPHARM(01177.HK) | Buy | 9.4 WUXI XDC(02268.HK) | Buy | 74 ~AAStocks Financial NewsWeb Site: www.aastocks.com...
24.12.25 - 04:00
Research: BofAS: CN Oct Drug Sales MoM Growth Significantly Slows; SINO BIOPHARM TP Cut to $8.3 (AAStocks)
 
The total sample drug sales in China's pharmaceutical industry declined by 3% YoY in October, a sharp drop from the 6.8% YoY growth in September, BofA Securities released a research report saying.HANSOH PHARMA (03692.HK) achieved the highest YoY incline among its peers in October, at 8.6%, the report noted. Most of HANSOH PH......
23.12.25 - 03:15
Research: CMBI Ratings, TPs on Pharmas (Table) (AAStocks)
 
Shares | Ratings | Target prices (HK$)3SBIO(01530.HK) | Buy | 37.58 GUSHENGTANG(02273.HK) | Buy | 44.95 WUXI XDC(02268.HK) | Buy | 74 SINO BIOPHARM(01177.HK) | Buy | 9.4 ~AAStocks Financial NewsWeb Site: www.aastocks.com...
11.11.25 - 05:00
Research: CMBI Envisions Recovery in 2H Results for CXO Firms, Favors SINO BIOPHARM/ WUXI XDC (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.25 - 10:30
Research: Guotai Junan Initiates Rating Buy on SINO BIOPHARM w/ TP HKD10 (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
30.09.25 - 05:30
Research: UBS Ratings/ TPs on CN Pharmas (Table) (AAStocks)
 
Stock | Rating | TP (HKD)HENGRUI PHARMA (01276.HK) | Buy | 97.8 HANSOH PHARMA (03692.HK) | Buy | 48.2 SINO BIOPHARM (01177.HK) | Buy | 12.23SBIO (01530.HK) | Buy | 41 CSPC PHARMA (01093.HK) | Buy -> Neutral | 10 SIMCERE PHARMA (02096.HK) | Buy | 16.3HENGRUI PHARMA (600276.SH) | Buy | RMB78.6 HUADONG MEDICINE (000963.SZ) | Buy......
16.09.25 - 04:00
TRANSTHERA-B Opens Up 15% to Hit New Highs, Surpassing SINO BIOPHARM, CSPC PHARMA in Mkt Cap w/ 35x Surge in Less Than 3 Mths Since Debut (AAStocks)
 
TRANSTHERA-B (02617.HK), a Chinese biopharmaceutical company that has been soaring in recent days, opened 15% higher today (16th) at another new high of HKD477.2, with a pre-market trading volume of 25,500 shares, involving HKD12.1686 million.TRANSTHERA-B was included in the list of securities eligible for Southbound Stock Conne......
11.09.25 - 07:00
H Shrs: HSI Falls 75 Pts at Midday; Pharmas Slide Across Board; Chips Rally (AAStocks)
 
The HSI ended the midday nearing its peak at 26,124, down 75 points or 0.3%. The HSCEI fell 44 points or 0.5% to 9,283. The HSTECH dropped 5 points or 0.1% to 5,897. The total market turnover for the half-day amounted to HKD176.337 billion.Pharma stocks were thrown into a downtrend. AKESO (09926.HK), SINO BIOPHARM (01177.HK), an......
09.09.25 - 05:00
Research: CMBI Recommends SINO BIOPHARM, INNOVENT BIO & 4 Other Parmas; Upbeat About Valuation Recovery in Consumer Healthcare (AAStocks)
 
CMBI has released a report analyzing the 1H25 results of 393 pharma firms listed in mainland China and Hong Kong. Their average revenue grew by 1.6%, while the average net profit declined by 3.2%. Both revenue and profit deteriorated compared to last year.In the broker's opinion, the pharma industry will require more time be......
08.09.25 - 10:15
Full-day Takeaway: HSI Closes at 25,633, Up 215 pts; HSTI Closes at 5,753, Up 66 pts; BABA Up over 4%; WUXI BIO, BOC HONG KONG, SINO BIOPHARM, CHOW TAI FOOK, SKYWORTH Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 215 pts or 0.8% to 25,633. HSTI rose 66 pts or 1.2% to 5,753. HSCEI gained 64 pts or 0.7% to 9,121. Market turnover reached $286.04 billion.Active Heavyweights:BABA (09988.HK) closed at $137.3, up 4.2%XIAOMI (01810.HK) closed at $54.75, up 2.1%TENCENT (00700.HK) closed at $617.5, up 2%PING AN (02318.HK) closed......
05.09.25 - 10:15
Full-day Takeaway: HSI Up 359 pts; HSTI Up 108 pts; XINYI SOLAR Up over 7%; SINO BIOPHARM, CHOW TAI FOOK, CALB, 3SBIO, KEYMED BIO-B Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 359 pts or 1.4% to 25,417. HSTI rose 108 pts or 1.9% to 5,687. HSCEI gained 120 pts or 1.3% to 9,057. Market turnover reached $299.95 billion.Active Heavyweights:TENCENT (00700.HK) closed at $605.5, up 2.2%MEITUAN (03690.HK) closed at $103, up 1.6%BABA (09988.HK) closed at $131.8, up 1.5%XIAOMI (01810.HK) clos......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!